Edesa Biotech, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Dr. Pardeep Nijhawan has increased his beneficial ownership in Edesa Biotech to 19.99% following a private placement and open market purchases.
NASDAQ
Velan Capital and its affiliates have increased their beneficial ownership in Edesa Biotech, Inc. to 9.99% of outstanding common shares.
NASDAQ
Dr. Pardeep Nijhawan and affiliated entities have increased their beneficial ownership in Edesa Biotech, Inc. to 19.99% through recent share purchases and RSU grants.
NASDAQ
SCHEDULE 13D: Velan Capital Takes Significant Stake in Edesa Biotech, Secures Board Representation and Governance Influence
Velan Capital and its affiliated entities have acquired a 9.99% beneficial ownership stake in Edesa Biotech, Inc. through a private placement, gaining a board seat and observer rights, citing the company's shares as undervalued.
NASDAQ
SCHEDULE 13D/A: Edesa Biotech Insider Dr. Pardeep Nijhawan Boosts Stake to 19.99% Through Private Placement and RSU Grants
Dr. Pardeep Nijhawan and affiliated entities have increased their beneficial ownership in Edesa Biotech, Inc. to 19.99% through recent restricted share unit grants and a private placement of Series B-1 Convertible Preferred Shares.